Bioxcel therapeutics announces first patient dosed in tranquility iii phase 3 trial for acute treatment of agitation in patients with alzheimer's disease

Pivotal trial will evaluate efficacy and safety of bxcl501 in alzheimer's patients in nursing homes with moderate to severe dementia

BTAI Ratings Summary

BTAI Quant Ranking